Abstract
Purpose
Febrile neutropenia is a potentially life threatening complication of breast cancer chemotherapy associated with a significant amount of morbidity, mortality, and health care resource utilization. Recent data on the national estimates of mortality rate, length of stay, and health care costs among the subpopulation of febrile neutropenia admissions with breast cancer are lacking.
Methods
We used the Nationwide Inpatient Sample database to identify patients with breast cancer hospitalized for febrile neutropenia from 2009 to 2011. We derived data on inhospital mortality rate, length of stay, and mean health care costs and compared it with previous studies.
Results
The average inhospital mortality rate during 2009–2011 was 2.6 % (n = 685). Advanced age (≥65 years) was found to be significantly associated with a higher odds of mortality (4.4 vs 1.7 %, OR 2.7, 95 % CI 2.3–3.1, p < 0.01). The mean length of stay was 5.7 days (95 % CI 5.5–5.9 days), whereas the mean cost of hospitalization was $37,087 (95 % CI $34,009–$40,165).
Conclusion
Febrile neutropenia-related hospitalizations continue to account for significant morbidity, mortality, and health care resource utilization among patients with breast cancer. Further efforts should be focused on curtailing the rising health care costs without compromising the quality of care.
This is a preview of subscription content, log in via an institution to check access.
References
Kozma CM, Dickson M, Chia V, Legg J, Barron R (2012) Trends in neutropenia-related inpatient events. J Oncol Pract 8(3):149–155
Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106(10):2258–2266
Michels SL, Barron RL, Reynolds MW, Smoyer Tomic K, Yu J, Lyman GH (2012) Costs associated with febrile neutropenia in the US. Pharmacoeconomics 30(9):809–823
HCUP Nationwide Inpatient Sample (NIS). Healthcare Cost and Utilization Project (HCUP). 2009–2011. Agency for Healthcare Research and Quality, Rockville, MD. Available at: www.hcup-us.ahrq.gov/nisoverview.jsp. Accessed 24 Apr 2014.
HCUP Clinical Classifications Software (CCS) for ICD-9-CM. Healthcare Cost and Utilization Project (HCUP). 2009–2011. Agency for Healthcare Research and Quality, Rockville, MD. Available at: www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp. Accessed 17 Mar 2014.
Klastersky J, Paesmans M, Rubenstein EB et al (2000) The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18(16):3038–3051
Clark OA, Lyman G, Castro AA, Clark LG, Djulbegovic B (2003) Colony stimulating factors for chemotherapy induced febrile neutropenia. Cochrane Database Syst Rev. (3):Cd003039
Dulisse B, Li X, Gayle JA et al (2013) A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia. J Med Econ 16(6):720–735
Elting LS, Rubenstein EB, Rolston KV, Bodey GP (1997) Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 25(2):247–259
Carratala J, Roson B, Fernandez-Sevilla A, Alcaide F, Gudiol F (1998) Bacteremic pneumonia in neutropenic patients with cancer: causes, empirical antibiotic therapy, and outcome. Arch Intern Med 158(8):868–872
Klastersky J, Paesmans M (2013) The multinational association for supportive care in cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer 21(5):1487–1495
Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT (2005) Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 103(9):1916–1924
Lyman GH, Michels SL, Reynolds MW, Barron R, Tomic KS, Yu J (2010) Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer 116(23):5555–5563
Kuderer NM, Dale DC, Crawford J, Lyman GH (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25(21):3158–3167
Mhaskar R, Clark OA, Lyman G, Engel Ayer Botrel T, Morganti Paladini L, Djulbegovic B (2014) Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Rev 10:Cd003039
Gandhi SK, Arguelles L, Boyer JG (2001) Economic impact of neutropenia and febrile neutropenia in breast cancer: estimates from two national databases. Pharmacotherapy 21(6):684–690
Schilling MB, Parks C, Deeter RG (2011) Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: a retrospective study. Exp Ther Med 2(5):859–866
Conflict of interest
Authors have no competing interests/financial disclosures to disclose.
Funding
There is no role of any funding agencies.
Contribution
RP and SG designed the study and prepared the initial draft. PK, MRA, and MGM drafted the final manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pathak, R., Giri, S., Aryal, M.R. et al. Mortality, length of stay, and health care costs of febrile neutropenia-related hospitalizations among patients with breast cancer in the United States. Support Care Cancer 23, 615–617 (2015). https://doi.org/10.1007/s00520-014-2553-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-014-2553-0